Application of PD‑L1 blockade in refractory histiocytic sarcoma: A case report

Imataki,Osamu; Uemura,Makiko; Fujita,Haruyuki; Kadowaki,Norimitsu

doi:10.3892/mco.2022.2569

Application of PD‑L1 blockade in refractory histiocytic sarcoma: A case report

Authors:
- Osamu Imataki
- Makiko Uemura
- Haruyuki Fujita
- Norimitsu Kadowaki
View Affiliations

Affiliations: Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kagawa 761‑0793, Japan
Published online on: July 15, 2022 https://doi.org/10.3892/mco.2022.2569
Article Number: 136
Copyright: © Imataki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histiocytic sarcoma (HS) is a rare hematological malignancy, which exhibits morphological and immunophenotypic features of histiocytes. A standard therapy for HS has not yet been established due to its rareness; therefore, disease control is not always possible. A multimodal treatment strategy has been suggested for HS. The present study reported on a case of a 43‑year‑old female patient who complained of left femoral pain, which was caused by left femoral bone mass. A biopsy of their left femoral bone tumor revealed that the patient had HS. Their sarcoma was localized in the femoral bone and was not considered to be curable, due to local infiltration of the bone tumor beyond the periosteum. The patient then underwent two types of HS‑specific chemotherapy; however, both regimens were ineffective. As a result, they underwent radiation therapy at the sites of progressive disease. Because the HS cells of the patient expressed PD‑L1, they were treated with nivolumab (240 mg/body, biweekly) for residual diseases in the right occipital bone, multiple lung nodules, intrapelvic right lymph node and primary site. Nivolumab treatment resulted in a complete response at all sites, with the exception of the primary site, which was confirmed by 18F‑fluorodeoxyglucose‑positron emission tomography/computed tomography. The patient received additional nivolumab treatment as consolidation therapy for 1 year. In addition, residual disease of the femoral head was completely resected. The surgically resected refractory tumor revealed the tumor cells no longer pathologically expressed PD‑L1 . In conclusion, for refractory and recurrent HS in which surgical resection is not appropriate, treatment with immune‑checkpoint inhibitors, such as nivolumab, may be considered an optional but promising immunotherapy if the tumor histologically expresses PD‑L1. The present study detected one of the refractory mechanisms of ICI treatment.

View Figures

View References

1	Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H and Thiele J: WHO classification of tumours of haematopoietic and lymphoid tissues. Revised Fourth Edition World Health Organization classification of tumours. IARC, Lyon, 2017.
2	Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES: The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.PubMed/NCBI View Article : Google Scholar
3	Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, et al: Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 127:2672–2681. 2016.PubMed/NCBI View Article : Google Scholar
4	Hung YP and Qian X: Histiocytic sarcoma. Arch Pathol Lab Med. 144:650–654. 2020.PubMed/NCBI View Article : Google Scholar
5	Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D and Arceci RJ: Disseminated histiocytoses biomarkers beyond BRAFV600E: Frequent expression of PD-L1. Oncotarget. 6:19819–19825. 2015.PubMed/NCBI View Article : Google Scholar
6	Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.PubMed/NCBI View Article : Google Scholar
7	Keir ME, Francisco LM and Sharpe AH: PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 19:309–314. 2007.PubMed/NCBI View Article : Google Scholar
8	May JM, Waddle MR, Miller DH, Stross WC, Kaleem TA, May BC, Miller RC, Jiang L, Strong GW, Trifiletti DM, et al: Primary histiocytic sarcoma of the central nervous system: A case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review. Radiat Oncol. 13(167)2018.PubMed/NCBI View Article : Google Scholar
9	Gounder M, Desai V, Kuk D, Agaram N, Arcila M, Durham B, Keohan ML, Dickson MA, D'Angelo SP, Shukla N, et al: Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. Eur J Cancer. 51:2413–2422. 2015.PubMed/NCBI View Article : Google Scholar
10	Iwabuchi H, Kawashima H, Umezu H, Takachi T, Imamura M, Saitoh A, Ogose A and Imai C: Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child. Int J Hematol. 106:299–303. 2017.PubMed/NCBI View Article : Google Scholar
11	Kommalapati A, Tella SH, Durkin M, Go RS and Goyal G: Histiocytic sarcoma: A population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood. 131:265–268. 2018.PubMed/NCBI View Article : Google Scholar
12	Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD, Griffiths E, Greer AH, Yin H, Peddi P and Shackelford RE: Histiocytic sarcoma as a secondary malignancy: Pathobiology, diagnosis, and treatment. Eur J Haematol. 97:9–16. 2016.PubMed/NCBI View Article : Google Scholar
13	Skala SL, Lucas DR and Dewar R: Histiocytic Sarcoma: Review, discussion of transformation from B-cell lymphoma, and differential diagnosis. Arch Pathol Lab Med. 142:1322–1329. 2018.PubMed/NCBI View Article : Google Scholar
14	Bose S, Robles J, McCall CM, Lagoo AS, Wechsler DS, Schooler GR and Van Mater D: Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma. Pediatr Blood Cancer. 66(e27491)2019.PubMed/NCBI View Article : Google Scholar
15	Tzankov A, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U and Hebeda KM: Histiocytic cell neoplasms involving the bone marrow: Summary of the workshop cases submitted to the 18th meeting of the European association for haematopathology (EAHP) organized by the European bone marrow working group, basel 2016. Ann Hematol. 97:2117–2128. 2018.PubMed/NCBI View Article : Google Scholar
16	Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Brüderlein S, Cario H, Lubatschofski A, Welke C, Anagnostopoulos I, et al: Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget. 5:4060–4070. 2014.PubMed/NCBI View Article : Google Scholar
17	Takahashi E and Nakamura S: Histiocytic sarcoma: An updated literature review based on the 2008 WHO classification. J Clin Exp Hematop. 53:1–8. 2013.PubMed/NCBI View Article : Google Scholar
18	Kommalapati A, Tella SH, Go RS and Goyal G: Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma. Leuk Lymphoma. 60:553–555. 2019.PubMed/NCBI View Article : Google Scholar
19	Shimono J, Miyoshi H, Arakawa F, Sato K, Furuta T, Muto R, Yanagida E, Sasaki Y, Kurita D, Kawamoto K, et al: Prognostic factors for histiocytic and dendritic cell neoplasms. Oncotarget. 8:98723–98732. 2017.PubMed/NCBI View Article : Google Scholar
20	Liu Z, Xiao Y, Liu X, Li Q, Liu T, Zhu F, Wu G and Zhang L: Case Report: Long-term response to radiotherapy combined with targeted therapy in histiocytic sarcoma harboring mutations in MAPK and PI3K/AKT pathways. Front Oncol. 11(755893)2021.PubMed/NCBI View Article : Google Scholar
21	Hu B, Patel JL, Tao R, Cannon RB, Monroe M and Goyal G: Near complete response to trametinib treatment in histiocytic sarcoma harboring a somatic KRAS mutation. J Natl Compr Canc Netw. 24:1–4. 2022.PubMed/NCBI View Article : Google Scholar
22	Branco B, Comont T, Ysebaert L, Picard M, Laurent C and Oberic L: Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature. Eur J Haematol. 103:444–448. 2019.PubMed/NCBI View Article : Google Scholar
23	Tomlin J, Orosco RK, Boles S, Tipps A, Wang HY, Husseman J and Wieduwilt M: Successful treatment of multifocal histiocytic sarcoma occurring after renal transplantation with cladribine, high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) followed by allogeneic hematopoietic stem cell transplantation. Case Rep Hematol. 2015(728260)2015.PubMed/NCBI View Article : Google Scholar
24	Gergis U, Dax H, Ritchie E, Marcus R, Wissa U and Orazi A: Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: A case report and review of the literature. J Clin Oncol. 29:e251–e253. 2011.PubMed/NCBI View Article : Google Scholar
25	Visonneau S, Cesano A, Tran T, Jeglum KA and Santoli D: Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104. Clin Cancer Res. 3:1789–1797. 1997.PubMed/NCBI